Antiviral therapy and fibrosis progression in patients with mild-moderate hepatitis C recurrence after liver transplantation. A randomized controlled study

Digestive and Liver Disease

Volumn 44, Issue 7, 2012, Pages 603-609

  Belli, Luca S ^a   Volpes, Riccardo ^b   Graziadei, Ivo ^c   Fagiuoli, Stefano ^d   Starkel, Peter ^e   Burra, Patrizia ^f   Alberti, Alberto B ^a   Gridelli, Bruno ^b   Vogel, Wolfgang ^c   Pasulo, Luisa ^d   De Martin, Eleonora ^f   Guido, Maria ^f   De Carlis, Luciano ^a   Lerut, Jan ^e   Cillo, Umberto ^f   Burroughs, Andrew K ^g   Pinzello, Giovambattista ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b MEDITERRANEAN INSTITUTE FOR TRANSPLANTATION AND ADVANCED SPECIALIZED THERAPIES ISMETT   (Italy)

^c UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^d OSPEDALI RIUNITI   (Italy)

^e CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^f UNIVERSITY OF PADOVA   (Italy)

^g Sheila Sherlock Liver Center   (United Kingdom)

Author keywords

HCV; PEG Interferon; Recurrent hepatitis; Ribavirin

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SCORING SYSTEM; TREATMENT RESPONSE;

ADULT; AGED; ANTIVIRAL AGENTS; BIOPSY; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; LIVER; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RECURRENCE; RIBAVIRIN; RNA, VIRAL; VIRAL LOAD;

EID: 84861347624     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2012.01.017     Document Type: Article

References (19)

1. Charlton M., Wiesner R.H. Natural history and management of hepatitis C infection after liver transplantation. Semin Liver Dis 2004, 24(Suppl. 2):79-88.
2. Berenguer M., Ferrell L., Watson J., et al. HCV-related fibrosis progression following liver transplantation increase in recent years. J Hepatol 2000, 32:673-684.
3. Forman L.M., Lewis J.D., Berlin J.A., et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002, 122:889-896.
4. Wiesner R.H., Sorrel M., Villamil F. Report of the first international liver transplant consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003, 9(Suppl. 3):S1-S9.
5. Berenguer M., Palau A., Fernanedz A., et al. Efficacy, predictors of response and potential risk associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2006, 12:1067-1076.
6. Samuel D., Forns X., Berenguer M., et al. Report of the monothematic conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006). J Hepatol 2006, 45:127-143.
7. Oton E., Barcena R., Moreno-Planas J.M., et al. Hepatitis C recurrence after liver transplantation: viral and histologic response to full dose PEG-Interferon and ribavirin. Am J Transpl 2006, 6:2348-2355.
8. Neumann U., Puhl G., Bahra M., et al. Treatment of patients with hepatitis C after liver transplantation with peginterferon a2B plus ribavirin. Transplantation 2006, 82:43-47.
9. Gordon F.D., Kwo P., Vargas H. Treatment of hepatitis C in liver transplant recipients. Liver Transpl 2009.
10. Wang C.S., Ko H.H., Yoshida E.M., et al. Interferon-based combination antiviral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transpl 2006, 6:1586-1599.
11. Ishak K.G., Baptista A., Bianchi L., et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995, 22:696-699.
12. Firpi R.J., Abdelmalek M.F., Soldevila-Pico C., et al. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl 2004, 10:1240-1247.
13. Carrion J.A., Navasa M., Garcia-Retortillo M., et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007, 132:1746-1756.
14. Samuel D., Bizollon T., Feray C., et al. Interferon a2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003, 124:642-650.
15. Bzowej N., Nelson D.R., Terrault N.A., et al. Phoenix: a randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl 2011, 17:528-538.
16. Gurusamy K.S., Osmani B., Xirouchakis E., et al. Antiviral therapy for recurrent liver graft infection with hepatitis C virus (review). Cochrane Libr 2009, http://www.thecochranelibrary.com.
17. Heydtmann M., Freshwater D., Dudley T., et al. Pegylated interferon alfa-2b for patients with HCV recurrence and graft fibrosis following liver transplantation. Am J Transpl 2006, 6:825-833.
18. Watt K., Veldt B., Charlton M. A practical guide to the management of HCV infection following liver transplantation. Am J Transpl 2009, 9:1707-1713.
19. Charlton M.R., Thompson A., Veldt B.J., et al. Interleukin 28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011, 53:317-324.